Clinical TrialSchizophreniaKetamineWithdrawn

Effects of acute ketamine administration on mental representations of the body in healthy participants.

This randomised controlled crossover trial (n=20) evaluated the safety and efficacy of ketamine for schizophrenia using 11mg/70kg ketamine.

Target Enrollment

20 participants

Study Type

interventional

Design

Randomized

Registry

Detailed Description

To determine whether or not acute ketamine administration produces schizophrenic-like changes in the way one's own body is represented mentally.

experimental

1. Pregnancy or currently breastfeeding
2. Neurological disorders or known seizure risk
3. History of loss of consciousness for over 5 mins
4. Current diagnosis or treatment for a mental illness
5. Past or current treatment for substance use disorder
6. Significant risk of psychoses (previous history of psychosis or first-degree relative diagnosed with schizophrenia/schizophrenia-spectrum disorders)
7. Presence or history of a kinetic disorder
8. Presence or history of hypertension
9. Presence or history of hepatic insufficiency
10. Presence of renal insufficiency
11. Presence or history of cardiovascular disorder
12. Significant risk of suicide
13. Known hypersensitivity to ketamine
14. Receiving any systematic prescription medication (excluding oral contraceptive pill)

Unknown facility — Australia